RxDoctor Payments Data

Scott Anderson, MD

Infectious Disease · Baton Rouge, LANPI 1114285293

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.3% of the total across 45 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 19.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $201 and has fallen 64.6% since, to $71 in 2025.

$937in general payments, 2019–2025

Across 45 payments — averaging $20.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$181
  • Amgen$132
  • Viiv Healthcare Company$61
  • Teva Pharmaceuticals USA, Inc.$60
  • Shionogi Inc$58
  • Insmed, Inc.$51
  • plus $394 from 16 others

What the payments were for

  • Food & beverage$92198%
  • Education$162%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$937 in reported general payments places this provider in the 55th percentile of 105 infectious disease providers in Louisiana.

See all infectious disease providers in Louisiana

Medicare billing

Part B allowed, 2024
$50,235
Medicare patients
117
Services billed
439

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxacillin Sodium24$21,185
Daptomycin58$16,696
ErtapenemErtapenem Sodium13$7,953
Cefepime Hcl44$7,127
Vancomycin Hcl21$5,586
Imipenem-Cilastatin SodiumImipenem/Cilastatin Sodium23$4,379
Linezolid26$2,748
CeftriaxoneCeftriaxone Sodium40$2,693
Doxycycline Hyclate108$2,561
Rifampin33$2,516
Ampicillin-SulbactamAmpicillin Sod/Sulbactam Sod11$2,422
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav24$1,670
Levofloxacin22$1,353
Clindamycin Hcl30$938
Minocycline Hcl18$862

Paid to pharmacies, not to this prescriber.

Other infectious disease in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →